GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 274
- Registration Number
- NCT00128492
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 382
- Registration Number
- NCT00117676
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 266
- Registration Number
- NCT00116805
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
- Conditions
- Waldenstrom Macroglobulinemia
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT00113802
- Locations
- 🇺🇸
Weill Medical College of Cornell/ New York Presbyterian Hospital, New York, New York, United States
🇺🇸Columbia University College of Physicans & Surgeons, New York, New York, United States
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo three times a day (TID)Drug: AZLI 75 mg three times a day (TID)
- First Posted Date
- 2005-06-02
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 166
- Registration Number
- NCT00112359
- Locations
- 🇺🇸
Children's Memorial Hospital / Northwestern University, Chicago, Illinois, United States
🇺🇸University of Missouri, Columbia, Missouri, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
- Conditions
- HIV Infections
- Interventions
- Drug: FTC/TDFDrug: FTC/TDF/EFV
- First Posted Date
- 2005-05-30
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 517
- Registration Number
- NCT00112047
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸AIDS Healthcare Foundation Research, Beverly Hills, California, United States
🇺🇸Capital Medical Associates, P.C., Washington, District of Columbia, United States
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
- Conditions
- HIV Infections
- First Posted Date
- 2005-03-24
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT00106379
- Locations
- 🇺🇸
Gary Richmond, MD, Fort Lauderdale, Florida, United States
🇺🇸Treasure Coast Infectious Disease Consultants, Vero Beach, Florida, United States
🇺🇸Fernando Garcia, MD, Harlingen, Texas, United States
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: Placebo two times a day (BID)/three times a day (TID)Drug: AZLI 75 mg two times a day (BID)/three times a day (TID)
- First Posted Date
- 2005-03-02
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 211
- Registration Number
- NCT00104520
- Locations
- 🇺🇸
Children's Hospital and Regional Medical Center, Seattle, Washington, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes
- First Posted Date
- 2004-12-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6560
- Registration Number
- NCT00099788
- Locations
- 🇺🇸
The TIMI Study Group, Boston, Massachusetts, United States
Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 173
- Registration Number
- NCT00095121